Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field
In the latest sign that the major biopharma players are eagerly joining the big tech rush on the gene therapy market, Pfizer has snagged an option to buy a Paris-based biotech with a lead program a rare liver disease.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
